Filters

B4GALNT4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

B4GALNT4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) size: 1.0 µg DNA 1125

Price 1125
Size 1.0 µg DNA
DNA lentivector for transduction information GENTAUR suggests to use our ABM packaging mix LV003 of second generation virusses or the LV053, This DNA can alos be used for packaging into Lentiviral particles for high efficiency transduction and stably integrated expressions, Vectors with selection markers like kanamycin, our 3rd Generation Packaging mixture, pLenti lentiviral plasmids DNAs are stored in 10milliMolar Tris/HCI with 1mM EDTA at a pH of 8 at -25 C, puromycin or cumate are available, Lentiveral packaging plasmid DNA for non-viral plasmid transfection and direct use in plasmid expression
Properties Depending on the epitopes used human ELISA kits can be cross reactive to many other species, Mainly analyzed are human serum, Modern , cDNA and human recombinants are used in human reactive ELISA kits and to produce anti-human mono and polyclonal antibodies, human cell culture supernatants and biological samples, plasma, primarily , saliva, urine,  , (Homo sapiens, Homo sapiens sapiens), Human proteins, humans , ssp
Gene targetB4GALNT4 Lentiviral Vector (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)
Short nameB4GALNT4 Lentiviral Vector ( ) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)
TechniqueVectors
Species Humans, Human
Alternative name sapiens) (cytomegalovirus) (pLenti-GIII-cytomegalovirus-Green Fluorescent-2A-Puro), B4GALNT4 Lentiviral integrating Desoxyribonucleic acid sequence (H
Identity 26315
Gene B4GALNT4
Long gene name beta-1, 4-N-acetyl-galactosaminyltransferase 4
Synonyms FLJ25045 NGalNAc-T1
Synonyms name N-acetyl-beta-glucosaminyl-glycoprotein 4-beta-N- acetylgalactosaminyltransferase
Locus 11p15, 5
Discovery year 2006-01-08
GenBank acession AB089939
Entrez gene record 338707
Pubmed identfication 15044014
RefSeq identity NM_178537
Classification Beta 4-glycosyltransferases
Havana BLAST/BLAT OTTHUMG00000119075

Subscribe to our Newsletter